Qizhi capsule

**Qizhi capsule** is a Chinese traditional medicine product developed by Shanghai Zhongyao Biotechnology for evaluation in metastatic castration-resistant prostate cancer. It has been studied as an oral adjunct to abiraterone acetate plus prednisone acetate in patients with prostate-specific antigen progression after prior abiraterone/prednisone therapy. The registered study is a randomized, double-blind, placebo-controlled, multicenter Phase IIa dose-exploration trial in patients characterized in traditional Chinese medicine as having stasis-heat internal accumulation syndrome. Its individual active constituents and molecular mechanism have not been reliably identified in public sources for the exact product named 七芝胶囊. ([synapse.zhihuiya.com](https://synapse.zhihuiya.com/drug/6c2395e4806e49d1a5503ac8b168f922))

Other names

七芝胶囊